Adenotonsillar disease

Area of Science:

• Otolaryngology
• Microbiology
• Immunology

Background:

• Adenotonsillar disease, including adenoiditis and recurrent tonsillitis, stems from chronic inflammation due to persistent bacterial infections.
• Bacteria like Staphylococcus aureus, Haemophilus sp., and Streptococcus sp. reside intracellularly and in mucosal biofilms, driving inflammation and lymphoid tissue hypertrophy.
• This hypertrophy causes symptoms such as upper airway obstruction, snoring, sleep apnea, sore throat, dysphagia, and halitosis.

Purpose of the Study:

• To review the role of bacterial persistence in mucosal biofilms in the etiology, diagnosis, and treatment of adenotonsillar disease.
• To discuss current and emerging treatment strategies targeting persistent bacteria.

Main Methods:

• Literature review focusing on bacterial persistence, biofilms, and adenotonsillar disease.
• Analysis of treatment modalities including antibiotics and surgical interventions.
• Consideration of relevant patents in the field.

Main Results:

• Bacterial persistence within biofilms and intracellularly is central to adenotonsillar disease pathogenesis.
• Antibiotics like macrolides (e.g., clarithromycin) can modulate immunity and interfere with bacterial signaling.
• Intracellularly active antibiotics (e.g., clindamycin) and surgical removal of hypertrophic tissue (e.g., laser tonsil ablation) are effective treatment options.

Conclusions:

• Effective treatment requires targeting bacteria within their biofilm or intracellular reservoirs.
• Surgical removal of hypertrophic tissue addresses both mechanical obstruction and the source of persistent infection.
• Understanding bacterial persistence is crucial for advancing the diagnosis and management of adenotonsillar disease.